Low investor expectation for Novo's study testing its weight loss drug in Alzheimer's disease, Leerink says
** Investor expectations for results from Novo Nordisk's NOVOb.CO late-stage trials testing its weight loss drug in patients with early Alzhimer's disease are low, analysts at Leerink Partners say
** If the trials surprisingly succeed, Eli Lilly's LLY.N stock could trade up on the notion that it could support longer-term patient adherence to GLP-1 drugs and give LLY validation to initiate studies in Alzhimer's disease with its own GLP-1 drugs: diabetes drug Mounjaro and weight-loss therapy Zepbound, brokerage says
** Novo is testing semaglutide, the active ingredient in its popular weight loss and diabetes drugs, to see if it can target neuroinflammation in Alzheimer's disease
** Trials are expected to be completed this month
** Clinical evidence to date of the utility of GLP-1 agonists in Alzheimer's disease patients is not robust - Leerink
** Results from Novo's trials "will provide very insightful results regardless of the outcome", brokerage says
** Companies are testing weight loss drugs in other conditions such as alcohol addiction and neurological disorders
** Up to last close, stock down 43.1% YTD
Related Articles
September Global Central Bank Divergence: How Will U.S. Stocks and Forex Markets Move?
TradingKey - Despite the divergence in monetary policies among major global central banks in September (with the Federal Reserve cutting rates while the European Central Bank, Bank of England, and Bank of Japan maintain steady rates), we expect the policy directions of the Fed, ECB, and BoE to...
Duolingo (DUOL): Can the Green Bird Fly High Again
TradingKey - Duolingo is a great business, despite the stock price being down nearly 50% from its peak less than four months ago. However, the question is whether it’s worth buying it at a market cap of $12.5 billion. The answer is “not yet” because the traffic, even though healthy...
U.S. September Rate Decision Preview: What It Means for Bitcoin and Could It Spark a New Rally?
Bitcoin’s rally stalls ahead of the Fed meeting — has the bullish momentum already been priced in?
UK July GDP Commentary: Can GBP Break Through Its Current Fluctuation?
After considering multiple factors, given the evident weakness on both sides of this currency pair, we expect the GBP/USD exchange rate to maintain its current fluctuation trend in the short term.
Fed to Cut Rates: All Asset Prices Up!
TradingKey - The Federal Reserve is almost certain to restart its interest rate cut cycle on 17 September this year. After in-depth research, we have concluded that cryptocurrencies, the broader U.S. stock market, and short-term U.S. Treasury bonds will all go up.
